Evaluates tolerability and reasons for discontinuation of foslevodopa infusion in Parkinson’s disease, indicating important patient experiences.
To evaluate the tolerability, patient-reported side effects and reasons for discontinuation of foslevodopa/foscarbidopa continuous subcutaneous infusion (LDp/CDp CSI) beyond the titration phase in a real-world cohort of people with Parkinson’s disease (PwP).
No takes yet. Share an insight, caveat, or question.
Rukavina et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: